As filed with the Securities and Exchange Commission on November 30, 2007

 

Registration No. 333-

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM S-8

 

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

 


 

 

 

IMMUNOGEN, INC.
(Exact Name of Registrant as Specified in its Charter)

 

Massachusetts
(State of Incorporation)

 

04-2726691
(I.R.S. Employer Identification Number)

 

 

 

128 Sidney Street

Cambridge, Massachusetts 02139

(617) 995-2500

(Address of Principal Executive Offices)

 

IMMUNOGEN, INC.
2006 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN

(Full Title of the Plan)


 

 

 

Craig Barrows

Vice President, General Counsel and Secretary
ImmunoGen, Inc.
128 Sidney Street

Cambridge, Massachusetts 02139
(617) 995-2500

(Name, Address and Telephone Number, Including Area Code, of Agent for Service)

 

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered

 

Amount to be Registered
(1)(2)

 

Proposed Maximum
Offering Price Per Share (3)

 

Proposed Maximum Aggregate Offering Price (3)

 

Amount of
Registration Fee (4)

 

Common Stock

 

811,245

 

$4.91

 

$3,983,213

 

$0

 


(1)

 

All of the 811,245 shares of the registrant’s common stock listed were part of the shares previously registered by registrant on Form S-8 (File No. 333-122553 filed on February 4, 2005) in connection with the registrant’s Restated Stock Option Plan, as amended (the “Original Registration Statement”).

 

 

 

(2)

 

In addition, pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an indeterminate number of additional shares of common stock to be offered or sold as a result of the anti-dilution provisions of the employee benefit plan described herein, including to prevent dilution resulting from any reorganization, recapitalization, reclassification, stock dividend, stock split or other similar change.

 

 

 

(3)

 

Calculated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of determining the amount of the registration fee, based on the average of the high and low prices on the NASDAQ Global Market on November 26, 2007.

 

 

 

(4)

 

The total registration fee for the shares being registered hereby is $122.29. An aggregate filing fee of $671.25 previously paid by the registrant in connection with the registration of the shares being carried forward from the Original Registration Statement is offset against the filing fee for this registration statement.

 

 



 

EXPLANATORY NOTE

                This registration statement is being filed solely for the purpose of registering 811,245 additional shares of common stock, par value $.01 per share (the “Common Stock”), of ImmunoGen, Inc. (the “Company”) to be offered to participants under the Company’s 2006 Employee, Director and Consultant Equity Incentive Plan (the “2006 Plan”), originally adopted in 2006.  The maximum number of shares of Common Stock reserved and available for issuance under the 2006 Plan includes 2,500,000 shares, which were previously registered with the Securities and Exchange Commission (the “Commission”) on Form S-8 (File No. 333-138713 filed on November 15, 2006) (the “2006 Registration Statement”), plus the number of shares underlying any grants previously made under the Company’s Restated Stock Option Plan (the “Restated Stock Option Plan”) that are forfeited, canceled or are terminated (other than by exercise) from and after November 11, 2006.  An aggregate of 811,245 additional shares have been included in the shares reserved for issuance under the 2006 Plan as a result of the forfeiture, cancellation or termination (other than by exercise), during the period between November 11, 2006 and October 31, 2007, of grants previously made under the Restated Stock Option Plan.

                Pursuant to General Instruction E of Form S-8, the contents of the 2006 Registration Statement are incorporated herein by reference, except as otherwise noted below.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

ITEM 3.  INCORPORATION OF DOCUMENTS BY REFERENCE.

The following documents are incorporated herein by reference:

 

(a)

 

The Company’s annual report on Form 10-K for the fiscal year ended June 30, 2007, filed with the Commission on August 30, 2007;

 

 

 

(b)

 

The Company’s quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2006, filed with the Commission on November 7, 2007;

 

 

 

(c)

 

The Company’s current reports on Form 8-K filed with the Commission on July 26, 2007, July 31, 2007, August 1, 2007, October 17, 2007, October 25, 2007 and November 19, 2007; and

 

 

 

(d)

 

The description of the Company’s common stock contained in the Company’s registration statement on Form 8-A, filed with the Commission on September 25, 1989, as amended by Amendment No. 1 thereto, filed with the Commission on November 15, 1989, pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment thereto or report filed for the purpose of updating such description.

 

All documents subsequently filed by the Company pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents.

ITEM 5.  INTERESTS OF NAMED EXPERTS AND COUNSEL.

Craig Barrows, Vice President, General Counsel and Secretary of the Company, has given his opinion on the validity of the Common Stock offered under this registration statement.  Mr. Barrows beneficially owns no shares of common stock of the Company.

ITEM 8.  EXHIBITS.

Exhibit

 

Description

 

 

 

4.1

 

Restated Articles of Organization (incorporated herein by reference to Exhibit 3.1 of the Company’s registration statement on Form S-1 (File No. 33-38883)).

 

 

1



 

4.2

 

Articles of Amendment to Restated Articles of Organization (incorporated herein by reference to Exhibit 3.1 of the Company’s quarterly report on Form 10-Q for the fiscal quarter ended December 31, 2001, as filed with the Commission on February 14, 2002).

 

 

 

4.3

 

By-laws, as amended through April 4, 2007 (incorporated herein by reference to Exhibit 3.1 of the Company’s current report on Form 8-K, as filed with the Commission on April 6, 2007).

 

 

 

4.4

 

Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.2 of the Company’s registration statement on Form S-1 (File No. 33-31219)).

 

 

 

4.6

 

ImmunoGen, Inc. 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

5.1*

 

Opinion of General Counsel.

 

 

 

23.1*

 

Consent of Ernst & Young LLP.

 

 

 

23.2

 

Consent of General Counsel (contained in the opinion filed as Exhibit 5.1 to this registration statement).

 

 

 

24.1

 

Power of Attorney (included in signature page to this registration statement).

 

 

 

99.1

 

Form of Incentive Stock Option Agreement under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.2 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.2

 

Form of Non-Qualified Stock Option Agreement under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.3 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.3

 

Form of Incentive Stock Option Agreement for Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.4 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.4

 

Form of Non-Qualified Stock Option Agreement for Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.5 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.5

 

Form of Non-Qualified Stock Option Agreement for Directors under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.6 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.6

 

Form of Restricted Stock Agreement for Non-Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.7 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.7

 

Form of Restricted Stock Agreement for Directors under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.8 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.8

 

Form of Restricted Stock Agreement for Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.9 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

____________________

*Filed herewith

 

2



 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, the Commonwealth of Massachusetts on this 30th day of November, 2007.

 

IMMUNOGEN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Daniel M. Junius

 

 

Daniel M. Junius

 

 

Executive Vice President and Chief Financial Officer

 

 

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Mitchel Sayare and Daniel M. Junius his or her true and lawful attorneys-in-fact and agents, each acting alone, with full powers of substitution and resubstitution, for him or her or in his or her  name, place and stead, in any and all capacities to sign any and all amendments or post-effective amendments to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, each acting alone, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

/s/ Mitchel Sayare

 

Chairman of the Board, President, Chief Executive

 

November 30, 2007

Michel Sayare

 

Officer and Director (Principal Executive Officer)

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Daniel M. Junius

 

Executive Vice President and Chief Financial

 

November 30, 2007

Daniel M. Junius

 

Officer (Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

/s/ David W. Carter

 

Director

 

November 30, 2007

David W. Carter

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Stephen C. McCluski

 

Director

 

November 30, 2007

Stephen C. McCluski

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Nicole Onetto

 

Director

 

November 30, 2007

Nicole Onetto

 

 

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Mark Skaletsky

 

Director

 

November 30, 2007

Mark Skaletsky

 

 

 

 

 

 

3



 

 

 

 

 

 

/s/ Joseph J. Villafranca

 

Director

 

November 30, 2007

Joseph J. Villafranca

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Director

 

 

Richard J. Wallace

 

 

 

 

 

 

 

 

 

 

4



 

EXHIBIT INDEX

Exhibit

 

Description

 

 

 

4.1

 

Restated Articles of Organization (incorporated herein by reference to Exhibit 3.1 of the Company’s registration statement on Form S-1 (File No. 33-38883)).

 

 

 

4.2

 

Articles of Amendment to Restated Articles of Organization (incorporated herein by reference to Exhibit 3.1 of the Company’s quarterly report on Form 10-Q for the fiscal quarter ended December 31, 2001, as filed with the Commission on February 14, 2002).

 

 

 

4.3

 

By-laws, as amended through April 4, 2007 (incorporated herein by reference to Exhibit 3.1 of the Company’s current report on Form 8-K, as filed with the Commission on April 6, 2007).

 

 

 

4.4

 

Form of Common Stock Certificate (incorporated herein by reference to Exhibit 4.2 of the Company’s registration statement on Form S-1 (File No. 33-31219)).

 

 

 

4.6

 

ImmunoGen, Inc. 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

5.1*

 

Opinion of General Counsel.

 

 

 

23.1*

 

Consent of Ernst & Young LLP.

 

 

 

23.2

 

Consent of General Counsel (contained in the opinion filed as Exhibit 5.1 to this registration statement).

 

 

 

24.1

 

Power of Attorney (included in signature page to this registration statement).

 

 

 

99.1

 

Form of Incentive Stock Option Agreement under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.2 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.2

 

Form of Non-Qualified Stock Option Agreement under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.3 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.3

 

Form of Incentive Stock Option Agreement for Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.4 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.4

 

Form of Non-Qualified Stock Option Agreement for Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.5 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.5

 

Form of Non-Qualified Stock Option Agreement for Directors under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.6 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.6

 

Form of Restricted Stock Agreement for Non-Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.7 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.7

 

Form of Restricted Stock Agreement for Directors under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.8 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

 

 

 

99.8

 

Form of Restricted Stock Agreement for Executives under the 2006 Employee, Director and Consultant Equity Incentive Plan (incorporated herein by reference to Exhibit 99.9 of the Company’s registration statement on Form S-8 (File No. 333-138713)).

____________________

*Filed herewith

 

5


Exhibit 5.1

November 30, 2007

ImmunoGen, Inc.

128 Sidney Street

Cambridge, MA 02139

 

Re:          Securities Being Registered Under Registration Statement on Form S-8

Ladies and Gentlemen:

I am Vice President, General Counsel and Secretary of ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and am issuing this opinion in connection with the filing of a Registration Statement on Form S-8 (the “Registration Statement”), for the purpose of registering with the Securities and Exchange Commission, under the Securities Act of 1933, as amended (the “Securities Act’), 811,245 shares (the “Shares”) of the Company’s common stock, par value $.01 per share (the “Common Stock”), issuable upon the exercise of options which may be granted under the Company’s 2006 Employee, Director and Consultant Equity Incentive Plan (the “Plan”), or upon the grant or vesting of restricted stock or other stock-based awards under the Plan.

In connection with this opinion, I have examined originals or copies, certified or otherwise identified to my satisfaction, of such corporate records of the Company and such other documents, records, certificates and other instruments of officials of the Company, public officials and others as I have deemed necessary or appropriate as a basis for the opinion set forth herein.  I have assumed the genuineness of all signatures, the authenticity of all documents submitted to me as originals and the conformity to authentic original documents of all copies submitted to me as conformed and certified or reproduced copies.  As to any facts material to the opinion expressed herein which I have not independently established or verified, I have relied upon statements and representations of officers and other representatives of the Company and others.

I am admitted to the practice of law in the Commonwealth of Massachusetts, and I express no opinion with respect to any other laws.

Based on the foregoing, I am of the opinion that the Shares have been duly authorized for issuance by the Company and, upon issuance and delivery against payment therefor in accordance with the terms of the Plan and the applicable option or award agreement, such Shares will be validly issued, fully paid and nonassessable shares of Common Stock.

I hereby consent to the filing of this opinion as an exhibit to the Registration Statement.  In giving my consent, I do not thereby admit that I am included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations promulgated thereunder.

Sincerely,

 

/s/ Craig Barrows

 

 

Craig Barrows

Vice President, General Counsel and Secretary

 


 

EXHIBIT 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2006 Employee, Director and Consultant Equity Incentive Plan of ImmunoGen, Inc. of our reports dated August 28, 2007, with respect to the consolidated financial statements and schedule of ImmunoGen, Inc. included in its Annual Report (Form 10-K) for the year ended June 30, 2007, and the effectiveness of internal control over financial reporting of ImmunoGen, Inc., filed with the Securities and Exchange Commission.

 

/s/ Ernst & Young LLP

 

 

 

 

 

Boston, Massachusetts

 

November 27, 2007